

| Basic information   |                     |
|---|---------------------|
| <b>2020/0311(CNS)</b><br><br>CNS - Consultation procedure<br>Directive  | Procedure completed |
| Temporary measures in relation to value added tax for COVID-19 vaccines and in vitro diagnostic medical devices<br><br><b>Subject</b><br><br>2.70.02 Indirect taxation, VAT, excise duties<br>4.20.01 Medicine, diseases<br><br><b>Legislative priorities</b><br><br><a href="#">The EU's response to the Covid-19 pandemic</a> |                     |

| Key players                   |   |  |                               |
|-------------------------------|---|--|-------------------------------|
| European Parliament           | <b>Committee responsible</b>                            |  | <b>Rapporteur</b>             |
|                               | <div>ECON</div> Economic and Monetary Affairs           |  |                               |
|                               | <b>Committee for opinion</b>                            |  | <b>Rapporteur for opinion</b> |
|                               | <div>IMCO</div> Internal Market and Consumer Protection |  |                               |
| Council of the European Union | <b>Council configuration</b>                            |  | <b>Meetings</b>               |
|                               | Economic and Financial Affairs ECOFIN                   |  | 1294                          |
|                               |   |  | <b>Date</b>                   |
|                               |   |  | 2020-12-01                    |
| European Commission           | <b>Commission DG</b>                                    |  | <b>Commissioner</b>           |
|                               | Taxation and Customs Union                              |  | GENTILONI Paolo               |